Literature DB >> 12116350

Evaluation of stabilized blood cell products as candidate preparations for quality assessment programs for CD4 T-cell counting.

Michèle Bergeron1, Atousa Shafaie, Tao Ding, Sieglinde Phaneuf, Nadia Soucy, Francis Mandy, John Bradley, John Fahey.   

Abstract

BACKGROUND: Exceptionally robust cell preparations are needed for quality assessment programs (QAPs) such as the International Program for Quality Assessment and Standardization for Immunological Measures (QASI) relevant to HIV/AIDS. A suitable product must withstand environmental stress related to transportation for a minimum of 6 days. The two objectives of this study are (1) to evaluate the performance of various commercial preparations with multicenter participation and (2) to evaluate the robustness of stabilized blood cell products.
METHODS: Phase 1: The performance of stabilized blood cell products was evaluated in a multicenter QAP utilizing various staining procedures and flow cytometers. Absolute cell enumeration was achieved using single-platform T-cell subset methodology. Phase 2: The robustness of stabilized blood cell products was evaluated by monitoring T-cell subset values from samples stored at 4 degrees C, 22 degrees C, and 37 degrees C for up to 10 days.
RESULTS: The largest interlaboratory variation in both absolute and relative T-cell values was 16% in samples with CD4 levels > or =400 cells per microliter and 21% in samples with CD4 levels <400 cells per microliter. Six preparations retained their phenotypic expression for 7 days at 4 degrees C and 22 degrees C. However, only two preparations remained stable for 4 days at 37 degrees C.
CONCLUSION: Some stabilized cell preparations are more robust and therefore more suitable for quality assessment purposes. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116350     DOI: 10.1002/cyto.10090

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  4 in total

Review 1.  Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development.

Authors:  Meina Liang; Martin Schwickart; Amy K Schneider; Inna Vainshtein; Christopher Del Nagro; Nathan Standifer; Lorin K Roskos
Journal:  Cytometry B Clin Cytom       Date:  2015-07-31       Impact factor: 3.058

2.  [External evaluation of the quality of CD4 T cells enumeration in the laboratory of immunology and hematology at the Cocody University Hospital Center].

Authors:  Koffi N'guessan; Yekayo Benedicte Koné; Oppong Richard Yéboah; Amah Patricia Goran-Kouacou; Séry Romuald Dassé
Journal:  Pan Afr Med J       Date:  2018-07-06

3.  Compatibility of stabilized whole blood products with CD4 technologies and their suitability for quality assessment programs.

Authors:  Tao Ding; Michèle Bergeron; Peggy Seely; Xuefen Yang; Tamsir O Diallo; Margot Plews; Paul Sandstrom; T Blake Ball; Adrienne F A Meyers
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

4.  Enumeration of circulating fibrocytes for clinical use in asthma by an optimized single-platform flow cytometry assay.

Authors:  Lorenza Bianchetti; Mirko Isgrò; Maurizio A Marini; Alberto Bellini; Matthias Schmidt; Sabrina Mattoli
Journal:  BBA Clin       Date:  2014-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.